advertisement

Topcon

Abstract #9910 Published in IGR 5-3

Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma

Pillunat LE; Larsson LI
British Journal of Ophthalmology 2003; 87: 1492-1496


AIMS: To evaluate the efficacy and safety of replacing current dual ocular hypotensive therapy with latanoprost 0.005% monotherapy in patients with open angle glaucoma. METHODS: This randomized, open label, parallel group, multinational study included 466 patients with open angle glaucoma currently on dual ocular hypotensive therapy, including a beta adrenergic receptor antagonist. Patients were assigned (1:3) to ongoing dual therapy or a switch to monotherapy with latanoprost 0.005% once daily for six months. Intraocular pressure (IOP) was measured at 10 am and 5 pm at baseline, month 3, and month 6. Groups were compared for differences in diurnal IOP change, IOP success rates (IOP ≤22 mmHg with ≤15% increase from baseline), and clinical success rates (not requiring change in therapy). RESULTS: Baseline mean diurnal IOP was 17.8 (SD 2.0) mmHg in the latanoprost group and 17.6 (2.1) mmHg in the dual therapy group. After six months, mean diurnal IOP was reduced by 0.26 (0.18) (SEM 1.4%) mmHg (p = 0.153) in the group switched to latanoprost and by 0.37 (0.25) (2.1%) mmHg (p = 0.138) in those continuing dual therapy (difference: 0.11 mmHg; p = 0.641). Success rates defined by IOP criteria were 83% for latanoprost and 89% for continued dual therapy (difference: 6%; p = 0.122). Clinical success rates were 97% for latanoprost and 99% for dual therapy (difference: 2%; p = 0.161). Ocular adverse events were reported by 23% of patients in both treatment groups. CONCLUSION: Latanoprost monotherapy is a safe and effective alternative for many patients with open angle glaucoma requiring dual topical ocular hypotensive therapy for IOP control.

Dr. L.E. Pillunat, Department of Ophthalmology, Augenklinik der Techn, Universitat Dresden, Germany


Classification:

11.4 Prostaglandins (Part of: 11 Medical treatment)



Issue 5-3

Change Issue


advertisement

Oculus